In this editorial, we emphasise the efficacy and challenges of using ketamine in treatment-resistant depression. We highlight the need for comprehensive evidence-based guidelines to manage the use of both licensed and off-licence ketamine formulations and discuss recent efforts by Beaglehole et al to develop ketamine guidelines in New Zealand. We finally advocate for national registries to monitor ketamine therapy, ensuring its responsible and effective use in the management of depression.

Original languageEnglish
Article numbere107
Pages (from-to)e107
JournalBJPsych Open
Issue number3
Publication statusPublished - 10 May 2024


Dive into the research topics of 'Guidelines for ketamine use in clinical psychiatry practice'. Together they form a unique fingerprint.

Cite this